Clinical trials: Hereditary Colorectal Cancer
Lynch Syndrome, Endometrial Neoplasms
Universal Screening for Lynch Syndrome in Women With Endometrial and Non-Serous Ovarian Cancer
This study will maximize identification of women with Lynch Syndrome using an enhanced screening strategy to identify those at risk.
- Conditions
- Lynch Syndrome, Endometrial Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms
- Trial name
- LS2 (NCT02494791)
- Testing
- Questionnaire, Educational Material
- Where
- Canada
- Volunteers
- 886 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Familial Adenomatous Polyposis, Colorectal Cancer
Multimedia Intervention in Patients With Familial Adenomatous Polyposis (FAP)
The goal of this research study is to test the first version of a website that will offer information and support for adolescents and young adults with FAP.
- Trial name
- NCT00525655
- Testing
- Web-Based Multimedia Intervention, Questionnaire
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- M.D. Anderson Cancer Center
Constitutional Mismatch Repair Deficiency Syndrome, Hematopoietic and Lymphoid Cell Neoplasm
Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study
This phase Ib trial investigates the side effects of the combination of nivolumab and ipilimumab, and to see how well they work in treating patients with cancers that have come back (relapsed) or does not respond to treatment…
- Conditions
- Constitutional Mismatch Repair Deficiency Syndrome, Hematopoietic and Lymphoid Cell Neoplasm, Lynch Syndrome, Recurrent Lymphoma
- Trial name
- NCT04500548
- Testing
- Biospecimen Collection, Ipilimumab, Nivolumab
- Where
- 9 sites in United States, Canada
- Sponsor
- National Cancer Institute (NCI)
Adenomatous Polyps
Detection of Ileoanal Pouch/Reservoir Adenomas
The detection of adenomas is the basis for the follow-up of patients with familial adenomatous polyposis, after colectomy, with a remnant rectum or an ileal pouch. The optimal method for the adenomas detection is not defined yet.
- Trial name
- DARIAC (NCT05954949)
- Testing
- Adenomas detection rate with the different observation methods
- Volunteers
- 40 people
- Sponsor
- Jean Christophe Saurin
Microsatellite Instability, Lynch Syndrome
MSI in Circulatory DNA of Endometrial Cancer
This study aims to analyze the microsatellite instability (MSI) in the circulatory tumor DNA and in the tumor tissue in the patients diagnosed with uterine endometrial cancer.
- Conditions
- Microsatellite Instability, Lynch Syndrome, Endometrial Cancer, Circulating Tumor Cell
- Trial name
- NCT03744962
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Lei Li
Familial Adenomatous Polyposis, Duodenal Neoplasms
Prevention of Progression of Duodenal Adenomas in Patients With Familial Adenomatous Polyposis
Duodenal carcinomas are the leading cause of mortality in patients with Familial Adenomatous Polyposis (FAP) who underwent prophylactic colorectal surgery.
- Conditions
- Familial Adenomatous Polyposis, Duodenal Neoplasms, Duodenal Polyps
- Trial name
- PreDuoFAP (NCT00808743)
- Testing
- Celecoxib, Ursodeoxycholic acid
- Where
- 5 sites in Netherlands
- Volunteers
- 37 people
- Sponsor
- Radboud University Medical Center
Colorectal Neoplasms
A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer
The purpose of this study is to evaluate relatlimab in combination with nivolumab, administered as a fixed-dose combination (nivolumab-relatlimab FDC, also referred to as BMS-986213) for the treatment of non-microsatellite…
- Trial name
- RELATIVITY-123 (NCT05328908)
- Testing
- Nivolumab-relatlimab FDC, Regorafenib, TAS-102
- Where
- 139 sites in United States, Argentina and 20 more
- Volunteers
- 769 people
- Sponsor
- Bristol-Myers Squibb
Lynch Syndrome, FAP
Hereditary Colorectal and Associated Tumor Registry Study
After informed consent, participants will be asked to complete a medical/family history questionnaire and provide a blood sample.
- Conditions
- Lynch Syndrome, FAP, Hereditary Diffuse Gastric Cancer, Juvenile Polyposis Syndrome
- Trial name
- NCT00633607
- Testing
- Research Registry
- Where
- United States
- Volunteers
- 114 people
- Sponsor
- University of Pittsburgh
Familial Adenomatous Polyposis
Microbial and Environmental Factors Associated With Polyps Development in Familial Adenomatous Polyposis (MicrobEnvironment in FAP)
Familial adenomatous polyposis (FAP) is an autosomal dominant inherited disorder linked to a mutation in the APC gene, associated with the development of multiple colonic and duodenal adenomas, which in 100% of cases progress to…
- Trial name
- NCT06614738
- Testing
- Sampling of feces and duodenal fluids
- Where
- 2 sites in France
- Volunteers
- 100 people
- Sponsor
- Hospices Civils de Lyon
Microsatellite Stable (MSS) Colon Cancer, Locally Advanced Colon Cancer
Node-Sparing Short-Course Radiation With CAPOX and Sintilimab for MSS Locally Advanced Colon Cancer: A Randomized, Prospective, Multicenter Study
This study aims to evaluate the use of node-sparing short-course radiotherapy combined with chemotherapy and Sintilimab, or chemotherapy alone, as neoadjuvant therapy for MSS-type locally advanced colon cancer.
- Trial name
- mRCAT-C (NCT06594692)
- Testing
- Node-Sparing Short-Course Radiotherapy Combined with CAPOX and Sintilimab, CAPOX Chemotherapy
- Where
- 2 sites in China
- Volunteers
- 140 people
- Sponsor
- Sir Run Run Shaw Hospital
Gardner Syndrome, Colorectal Carcinoma
A Cohort Study of Patients Treated With Brachytherapy for Selected Desmoid Patients in Gardner Syndrome
The purpose of this study is to assess the long-term outcome in a cohort of Gardner-Syndrome patients receiving prophylaxis and treatment for intestinal and non-intestinal tumors.
- Conditions
- Gardner Syndrome, Colorectal Carcinoma, Desmoid Tumor
- Trial name
- NCT01286662
- Volunteers
- 105 people
- Sponsor
- Triemli Hospital
Familial Breast Cancer, Familial Colorectal Cancer
Direct Information to At-risk Relatives
This study evaluates if uptake of genetic counselling in high-risk families is increased when patients at cancer genetics clinics are being offered healthcare-assisted disclosure to at-risk relatives compared to current standard…
- Conditions
- Familial Breast Cancer, Familial Colorectal Cancer, Hereditary Breast and Ovarian Cancer Syndrome, Hereditary Breast Cancer
- Trial name
- DIRECT (NCT04197856)
- Testing
- Standard care encouraging family-mediated disclosure of hereditary cancer risk, Offer of health-care assisted disclosure by sending direct letters to at-risk relatives
- Where
- Sweden
- Volunteers
- 490 people
- Sponsor
- Umeå University
Familial Adenomatous Polyposis
Niclosamide for Familial Adenomatous Polyposis
Familial adenomatous polyposis (FAP) leads to adenomas and eventual adenocarcinomas in colon and less frequently, duodenum. Chemopreventive strategies have been studied in FAP patients to delay the development of adenomas and…
- Trial name
- NCT04296851
- Testing
- Niclosamide
- Where
- South Korea
- Volunteers
- 72 people
- Sponsor
- Yonsei University
Cancer
High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill…
- Trial name
- NCT00002854
- Testing
- filgrastim, carboplatin, cisplatin
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- City of Hope Medical Center
Familial Adenomatous Polyposis
Use of Curcumin in the Lower Gastrointestinal Tract in Familial Adenomatous Polyposis Patients
The purpose of this study is to assess if curcumin, a commonly used food spice, can regress colorectal adenomatous polyps in patients with familial adenomatous polyposis, an inherited form of colorectal cancer.
- Trial name
- NCT00248053
- Testing
- curcumin
- Sponsor
- Johns Hopkins University
Colorectal Neoplasms
Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)
This trial will evaluate the safety and efficacy of vicriviroc (MK-7690) at 2 dose levels in combination with pembrolizumab (MK-3475) in participants with advanced/metastatic microsatellite stable (MSS) colorectal cancer (CRC).
- Trial name
- NCT03631407
- Testing
- Vicriviroc, Pembrolizumab
- Where
- 8 sites in United States, Canada
- Volunteers
- 41 people
- Sponsor
- Merck Sharp & Dohme LLC
Colorectal Cancer
Study Evaluating Biomarkers in Patients With Colorectal Cancer and Native KRAS Treated With Chemotherapy + Cetuximab
Advanced colorectal cancer (ACRC) is a heterogeneous disease and classification of patients is nowadays inefficient. Roughly twenty per cent of patients present with favorable figures (less than 4 liver nodules and less than 5…
- Trial name
- POSIBA (NCT01276379)
- Testing
- FOLFIRI (m), FOLFOX-6 (m), Cetuximab
- Where
- 27 sites in Spain
- Volunteers
- 221 people
- Sponsor
- Grupo Espanol Multidisciplinario del Cancer Digestivo
Colorectal Cancer Metastatic, Microsatellite Stable (MSS) Colorectal Cancer (CRC)
FOLFIRI Plus Bevacizuamb and QL1706 in Second-Line Treatment for mCRC
Thsi study is a randomised, parallel-controlled phase II/III trial evaluating FOLFIRI plus bevacizumab with or without QL1706 as second-line therapy for metastatic colorectal cancer. The primary endpoint is PFS.
- Trial name
- FIRBIT (NCT07729605)
- Testing
- FOLFIRI + bevacizumab + QL1706, FOLFIRI + bevacizumab
- Where
- China
- Volunteers
- 270 people
- Sponsor
- Sun Yat-sen University
Cancer, Pancreatic Cancer
9-ING-41 in Patients With Advanced Cancers
GSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in…
- Conditions
- Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer
- Trial name
- NCT03678883
- Testing
- 9-ING-41, Gemcitabine - 21 day cycle, Doxorubicin.
- Where
- 66 sites in United States, Belgium and 5 more
- Volunteers
- 350 people
- Sponsor
- Actuate Therapeutics Inc.
RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of pralsetinib (BLU-667)…
- Conditions
- RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer, RET-altered Colon Cancer
- Trial name
- ARROW (NCT03037385)
- Testing
- pralsetinib (BLU-667)
- Where
- 71 sites in United States, Belgium and 11 more
- Volunteers
- 590 people
- Sponsor
- Hoffmann-La Roche